Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Ongoing Brand or Portfolio Management

Sponsored by

Finalist

Revlimid

Celgene


Summary of work

Following NICE’s approval of Revlimid, for multiple myeloma (MM) in early 2009, we at Celgene set out to achieve not only increased access to the treatment, but also a whole new understanding of the disease itself. 

A full paradigm shift was required, from MM as an end-of-life condition, with a short-term approach and ‘treatment-free’ phases as the goal, to new understanding of it as a ‘chronic condition’ requiring continuous treatment – an entirely new concept for the medical profession and patients alike. 

Thus we worked tirelessly to educate the relevant communities on this new approach, to increase access while emphasising the importance of treatment duration to help drive overall survival – in which we now lead Europe, despite our third line (versus their second line) positioning. 

All the time, we demonstrated the value, efficacy and cost effectiveness of the treatment, even putting our money where our mouth is and offering Revlimid free of charge, after 26 cycles, through a pioneering Patient Access Scheme which is delivering exactly what we told NICE it would. 

As the first and only of its kind, the scheme and other learnings from the UK Revlimid approach are being viewed as best practice across Celgene Europe and by the UK oncology community.

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics